Free
Erratum  |   February 2002
AUTHOR CORRECTION
Article Information
Erratum
Erratum   |   February 2002
AUTHOR CORRECTION
Anesthesiology 2 2002, Vol.96, 522. doi:
Anesthesiology 2 2002, Vol.96, 522. doi:
For the article by Liu et al.  in the October 2001 issue of Anesthesiology (2001; 95:939–46), the legend to figure 3should have appeared as follows:
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
×
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
Fig. 3. Dose–response curve of the inhibitory effect of sevoflurane on hypoxic pulmonary vasoconstriction (HPV) in the absence and presence of potassium channel inhibitors, n = 8 per group. There are no significant differences among the groups. The concentration of sevoflurane that induced 50% inhibition of HPV (ED50) was 0.82 ± 0.21 MAC in the control-SEVO group, 0.87 ± 0.25 MAC in the Glib-SEVO group, 0.96 ± 0.24 MAC in the 4AP-SEVO group, and 0.76 ± 0.17 MAC in the IbTX-SEVO group. Glib = glibenclamide, the adenosine triphosphate–sensitive potassium (KATP)-channel inhibitor; 4-AP = 4-aminopyridine, the voltage-sensitive potassium (KV)-channel inhibitor; IbTX = iberiotoxin, the high-conductance calcium-activated potassium (KCa) channel inhibitor; SEVO = sevoflurane.
×